The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Roytman A.P.

Russian Medical Academy for Continuous Professional Education

Kuznetsova T.E.

Russian Medical Academy for Continuous Professional Education;
Sklifosovsky Research Institute for Emergency Medicine

Belyaev I.A.

Mandryk Central Military Clinical Hospital

Bugrov A.V.

Russian Medical Academy for Continuous Professional Education

Tazina S.Ya.

Sechenov First Moscow State Medical University

Dolgov V.V.

Russian Medical Academy for Continuous Professional Education

Godkov M.A.

Russian Medical Academy for Continuous Professional Education;
Sklifosovsky Research Institute for Emergency Medicine

Laboratory biomarkers for the prognosis of chronic heart failure

Authors:

Roytman A.P., Kuznetsova T.E., Belyaev I.A., Bugrov A.V., Tazina S.Ya., Dolgov V.V., Godkov M.A.

More about the authors

Journal: Laboratory Service. 2024;13(3): 5‑16

DOI: 10.17116/labs2024130315

Read: 1155 times

Buy for 300₽
Contact the author
Table of contents

LABORATORY BIOMARKERS FOR THE PROGNOSIS OF CHRONIC HEART FAILURE
LABORATORY BIOMARKERS FOR THE PROGNOSIS OF CHRONIC HEART FAILURE

To cite this article:

Roytman AP, Kuznetsova TE, Belyaev IA, Bugrov AV, Tazina SYa, Dolgov VV, Godkov MA. Laboratory biomarkers for the prognosis of chronic heart failure. Laboratory Service. 2024;13(3):5‑16. (In Russ.)
https://doi.org/10.17116/labs2024130315

Подписка 2025 Лабораторная служба (Laboratory Service)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
A middle-aged patient with early mani­festations of post-radiation constrictive peri­carditis: case report. Russian Cardiology Bulletin. 2024;(3):98-103
Prognostic scale for early dete­ction of various postoperative complications after thoracic aortic surgery: post-hoc analysis of biomarkers. Piro­gov Russian Journal of Surgery. 2024;(10):38-48
New aspe­cts of psoriasis pathogenesis: meta­bolomic profiling in dermatology. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):526-531
Diaphragm dysfunction as a prognostic criterion of exte­rnal respiratory impairment and nece­ssary extracorporeal membrane oxygenation in patients with chro­nic heart failure. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):38-45
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
The pote­ntials of the six-minute walking test in clinical practice auto­matization and adva­nced features. Russian Journal of Preventive Medi­cine. 2024;(12):122-127
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Inflammatory aging. Part 1. The principal biochemical mechanisms. Russian Journal of Preventive Medi­cine. 2024;(12):145-150
Prognosis and prevention of recu­rrent and atypical endo­metrial hype­rplasia in women of reproductive age. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):59-65
Abstract:

INTRODUCTION

Chronic heart failure (CHF) is a pressing worldwide medical problem, in our country in particular. The incidence of CHF is constantly increasing. The epidemiological forecast shows that by 2050, the number of patients with CHF will increase by 60% compared to 2010. According to the latest data, the total number of patients with CHF in Russia is 12 million, 4.5 million of whom have III and IV New York Heart Association (NYHA) functional class. Heart transplantation is a high-tech method of treating terminal heart failure and is recognized as the gold standard of care for patients whose risk of death within a year is more than 50% if it is impossible to use other methods of treatment. A number of new laboratory biomarkers can help predict adverse outcomes in patients with CHF.

OBJECTIVE

To summarize information about laboratory biomarkers for the assessment and prognosis of CHF and explaine the actuality of their further study in clinical practice.

MATERIAL AND METHODS

This review is based on articles over the past 10 years conducted using the resources of the PubMed and eLIBRARY research engines using keywords.

RESULTS

Existing laboratory markers used to assess and predict the course of CHF have a number of limits. The comparison of biomarkers made including diagnostic characteristics, the advantages and disadvantages of using biomarkers in clinical practice.

CONCLUSION

It is efficient to use several laboratory biomarkers to assess and predict the course of CHF. The most promising laboratory biomarkers for the assessment and prognosis of CHF are neprilysin, fractalkine, interleukin-6 and biomarkers of of extracellular matrix metabolism (MMP-2, MMP-8, PIIINP and TIMP-1).

Keywords:

chronic heart failure
biomarkers
sensitivity
specificity

Authors:

Roytman A.P.

Russian Medical Academy for Continuous Professional Education

Kuznetsova T.E.

Russian Medical Academy for Continuous Professional Education;
Sklifosovsky Research Institute for Emergency Medicine

Belyaev I.A.

Mandryk Central Military Clinical Hospital

Bugrov A.V.

Russian Medical Academy for Continuous Professional Education

Tazina S.Ya.

Sechenov First Moscow State Medical University

Dolgov V.V.

Russian Medical Academy for Continuous Professional Education

Godkov M.A.

Russian Medical Academy for Continuous Professional Education;
Sklifosovsky Research Institute for Emergency Medicine

Received:

09.07.2024

Accepted:

08.10.2024

Close metadata

References:

  1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2022;24(1):4-131.  https://doi.org/10.1002/ejhf.2333
  2. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Cardiac Failure Review. 2017;3(1):7-11. PMID: 28785469; PMCID: PMC5494150. https://doi.org/10.15420/cfr.2016:25:2
  3. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.). https://doi.org/10.15829/1560-4071-2020-4083
  4. Udelson JE. Heart failure with preserved ejection fraction. Circulation. 2011;124(21):e540-e543. https://doi.org/10.1161/CIRCULATIONAHA.111.071696
  5. Tanai E, Frantz S. Pathophysiology of Heart Failure. Comprehensive Physiology. 2015;6(1):187-214.  https://doi.org/10.1002/cphy.c140055
  6. Edvinsson ML, Ahnstedt H, Edvinsson L, Andersson SE. Characterization of Relaxant Responses to Natriuretic Peptides in the Human Microcirculation In Vitro and In Vivo. Microcirculation (New York NY.: 1994). 2016;23(6):438-446.  https://doi.org/10.1111/micc.12290
  7. De Vito P. Atrial natriuretic peptide: an old hormone or a new cytokine? Peptides, 2014;58:108-116.  https://doi.org/10.1016/j.peptides.2014.06.011
  8. Vetrone F, Santarelli S, Russo V, Lalle I, De Berardinis B, Magrini L, Di Stasio E, Salerno G, Cardelli P, Piccoli A, Codognotto M, Mion MM, Plebani M, Vettore G, Castello LM, Avanzi GC, Di Somma S. Copeptin decrease from admission to discharge has favorable prognostic value for 90-day events in patients admitted with dyspnea. Clinical Chemistry and Laboratory Medicine. 2014;52(10):1457-1464. https://doi.org/10.1515/cclm-2014-0207
  9. Kremneva LV. Significance of copeptin in diagnostics of myocardial infarction. Russian Journal of Cardiology. 2017;(11):93-97. (In Russ.). https://doi.org/10.15829/1560-4071-2017-11-93-97
  10. Palatkina LO, Korneyeva ON, Drapkina OM. Oxidative stress, its role in the pathogenesis of chronic heart failure, and potential methods of correction. Cardiovascular Therapy and Prevention. 2012;11(6):91-94. (In Russ.). https://doi.org/10.15829/1728-8800-2012-6-91-94
  11. Polunina EA, Voronina LP, Popov EA, Polunina OS. Analysis of the level of markers of oxidative stress in chronic heart failure depending on the left ventricular ejection fraction. Cardiovascular Therapy and Prevention. 2018;17(5):34-39. (In Russ.). https://doi.org/10.15829/1728-8800-2018-5-34-39
  12. Wert KJ, Velez G, Cross MR, Wagner BA, Teoh-Fitzgerald ML, Buettner GR, McAnany JJ, Olivier A, Tsang SH, Harper MM, Domann FE, Bassuk AG, Mahajan VB. Extracellular superoxide dismutase (SOD3) regulates oxidative stress at the vitreoretinal interface. Free Radical Biology & Medicine. 2018;124:408-419.  https://doi.org/10.1016/j.freeradbiomed.2018.06.024
  13. Sorop O, Heinonen I, van Kranenburg M, van de Wouw J, de Beer VJ, Nguyen ITN, Octavia Y, van Duin RWB, Stam K, van Geuns RJ, Wielopolski PA, Krestin GP, van den Meiracker AH, Verjans R, van Bilsen M, Danser A H. J, Paulus WJ, Cheng C, Linke WA, Joles JA, et al. Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovascular Research. 2018;114(7):954-964.  https://doi.org/10.1093/cvr/cvy038
  14. Osipova OA, Gosteva EV, Shepel RN, Serdyukova AV, Kryshka AA, Inshakova KYu, Ulyanova AYu, Brizhaneva AS, Saraev IA. Chronic heart failure with moderately low ejection fraction. Humans and Their Health. 2023;26(4):20-27. (In Russ.). https://doi.org/10.21626/vestnik/2023-4/02
  15. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circulation Research. 2015;116(7):1254-1268. https://doi.org/10.1161/CIRCRESAHA.116.302317
  16. Chiurchiù V, Leuti A, Saracini S, Fontana D, Finamore P, Giua R, Padovini L, Incalzi RA, Maccarrone M. Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2019;33(1):909-916.  https://pubmed.ncbi.nlm.nih.gov/30052486/
  17. Mongirdienė A, Liobikas J. Phenotypic and Functional Heterogeneity of Monocyte Subsets in Chronic Heart Failure Patients. Biology. 2022;11(2):195.  https://doi.org/10.3390/biology11020195
  18. Karetnikova VN, Kashtalap VV, Kosareva SN, Barbarash OL. Fibroz miokarda: sovremennye aspekty problemy Myocardial fibrosis: Current aspects of the problem]. Terapevticheskij arkhiv. 2017;89(1):88-93. (In Russ.). https://pubmed.ncbi.nlm.nih.gov/28635904/
  19. Wu CK, Su MM, Wu YF, Hwang JJ, Lin LY. Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients. Journal of Clinical Medicine. 2018;7(11):427.  https://doi.org/10.3390/jcm7110427
  20. Cypen J, Ahmad T, Testani JM, DeVore AD. Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports. 2017;14(5):434-443.  https://doi.org/10.1007/s11897-017-0358-4
  21. Ibrahim NE, Januzzi JL Jr. Established and Emerging Roles of Biomarkers in Heart Failure. Circulation Research. 2018;123(5):614-629.  https://doi.org/10.1161/CIRCRESAHA.118.312706
  22. Belenkov YuN, Privalova EV, Yusupova AO, Zhito AV. Markers of Vascular Wall Fibrosis Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Ischemic Heart Disease with and without Concomitant Type-2 Diabetes Mellitus. Kardiologiia. 2019;59(5):61-66. (In Russ.). https://doi.org/10.18087/cardio.2019.5.10258
  23. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, & van der Harst P. The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine. 2012;272(1):55-64.  https://doi.org/10.1111/j.1365-2796.2011.02476.x
  24. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics. 2001;69(3):89-95.  https://doi.org/10.1067/mcp.2001.113989
  25. Konradi AO. Biomarkers, types and role in personalized medicine. Russian Journal for Personalized Medicine. 2022;2(3):6-16 (In Russ.). https://doi.org/10.18705/2782-3806-2022-2-3-6-16
  26. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US), 2016. Accessed March 26, 2024. https://pubmed.ncbi.nlm.nih.gov/27010052
  27. Garg P, Morris P, Fazlanie AL, Vijayan S, Dancso B, Dastidar AG, Plein S, Mueller C, Haaf P. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Internal and Emergency Medicine. 2017;12(2):147-155.  https://doi.org/10.1007/s11739-017-1612-1
  28. Scheitz JF, Stengl H, Nolte CH, Landmesser U, Endres M. Neurological update: use of cardiac troponin in patients with stroke. Journal of Neurology. 2021;268(6):2284-2292. https://doi.org/10.1007/s00415-020-10349-w
  29. Zagidullin N, Motloch LJ, Gareeva D, Hamitova A, Lakman I, Krioni I, Popov D, Zulkarneev R, Paar V, Kopp K, Jirak P, Ishmetov V, Hoppe UC, Tulbaev E, & Pavlov V. Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. Journal of Clinical Medicine. 2020;9(2):550.  https://doi.org/10.3390/jcm9020550
  30. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115(8):949-952.  https://doi.org/10.1161/CIRCULATIONAHA.106.683110
  31. Drapkina OM, Shepel RN, Dzhioeva ON. Natriuretic peptides: new challenges — new solutions. Cardiovascular Therapy and Prevention. 2021;20(7):3102. (In Russ.). https://doi.org/10.15829/1728-8800-2021-3102
  32. Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nature reviews. Cardiology. 2020;17(11):698-717.  https://doi.org/10.1038/s41569-020-0381-0
  33. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. https://doi.org/10.1161/CIR.0000000000001063
  34. Myasoedova EI. Level of aurathrenomedullin in chronic heart failure of ischemic genesis: associations with clinical manifestations. Bulletin of Siberian Medicine. 2019;18(3):81-89. (In Russ.). https://doi.org/10.20538/1682-0363-2019-3-81-89
  35. Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews. 2022;27(2):625-643.  https://doi.org/10.1007/s10741-021-10105-w
  36. Huang Z, Zhong J, Ling Y, Zhang Y, Lin W, Tang L, Liu J, Li S. Diagnostic value of novel biomarkers for heart failure: A meta-analysis. Herz. 2020 Feb;45(1):65-78.  https://doi.org/10.1007/s00059-018-4702-6
  37. Ramanathan K, Padmanabhan G. Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review. Indian Heart Journal. 2020;72(1):14-19.  https://doi.org/10.1016/j.ihj.2020.01.0
  38. Bayés-Genís A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupón J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. Journal of the American College of Cardiology. 2015;65(7):657-665.  https://doi.org/10.1016/j.jacc.2014.11.048
  39. Núñez J, Núñez E, Barallat J, Bodí V, Miñana G, Pastor MC, Sanchis J, Lupón J, Bayes-Genis A. Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure. Journal of the American Heart Association. 2017;6(8):e005712. https://doi.org/10.1161/JAHA.117.005712
  40. Watanabe T. The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease. International Journal of Molecular Sciences. 2021;22(11):6118. https://doi.org/10.3390/ijms22116118
  41. Kamardinov DK, Songurov RN, Ioshina VI, Buziashvili YuI. Soluble ST2 — as a biomarker, a tool for risk stratification and therapeutic target in patients with chronic heart failure. Kardiologiia. 2020;60(2):111-121. (In Russ.). https://doi.org/10.18087/cardio.2020.2.n816
  42. Vergaro G, Gentile F, Aimo A, Januzzi JL Jr, Richards AM, Lam CSP, de Boer RA, Meems LMG, Latini R, Staszewsky L, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, Yoshihisa A, Takeishi Y, et al. Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure. ESC Heart Failure. 2022;9(4):2084-2095. https://doi.org/10.1002/ehf2.13883
  43. Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL Jr. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology. 2018;72(19):2309-2320. https://doi.org/10.1016/j.jacc.2018.08.2165
  44. Aimo A, Januzzi JL, Jr, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C, Emdin M. Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. Journal of the American College of Cardiology. 2019;74(17):2193-2203. https://doi.org/10.1016/j.jacc.2019.08.1039
  45. Traxler D, Zimmermann M, Simader E, Veraar CM, Moser B, Mueller T, Mildner M, Dannenberg V, Lainscak M, Jug B, Ankersmit HJ. The inflammatory markers sST2, HSP27 and hsCRP as a prognostic biomarker panel in chronic heart failure patients. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2020;510:507-514.  https://doi.org/10.1016/j.cca.2020.07.050
  46. Barutaut M, Fournier P, Peacock WF, Evaristi MF, Dambrin C, Caubère C, Koukoui F, Galinier M, Smih F, Rouet P. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. Acta Cardiologica. 2020;75(8):739-747.  https://doi.org/10.1080/00015385.2019.1669847
  47. Xiang Y, Zhang Z, Xie C, Wang L, Wu, Y, Zhan Y, Chen D. Serum Cat S, TSP-1, IL-11, BNP and sST2 Diagnostic and Prognostic Value in Chronic Heart Failure. Alternative Therapies in Health and Medicine. 2022;28(4):55-59. PMID: 35452416 
  48. Sedova NA, Roytman AP, Bugrov AV, Godkov MA. Clinical and laboratory complex for assessing the severity of chronic heart failure, burdened with metabolic syndrome. Laboratory Service. 2022;11(3):43-53. (In Russ.). https://doi.org/10.17116/labs20221103143
  49. Land H, Grez M, Ruppert S, Schmale H, Rehbein M, Richter D, Schütz G. Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA. Nature. 1983;302(5906):342-344.  https://doi.org/10.1038/302342a0
  50. Riddell DC, Mallonee R, Phillips JA, Parks JS, Sexton LA, Hamerton JL. Chromosomal assignment of human sequences encoding arginine vasopressin-neurophysin II and growth hormone releasing factor. Somatic Cell and Molecular Genetics. 1985;11(2): 189-195.  https://doi.org/10.1007/BF01534707
  51. Sklar AH, Schrier RW. Central nervous system mediators of vasopressin release. Physiological Reviews. 1983;63(4):1243-1280. https://doi.org/10.1152/physrev.1983.63.4.1243
  52. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. The American Journal of Physiology. 1979;236(4):F321-F332. https://doi.org/10.1152/ajprenal.1979.236.4.F321
  53. Birnbaumer M. Vasopressin receptors. Trends in Endocrinology and Metabolism: TEM. 2000;11(10):406-410.  https://doi.org/10.1016/s1043-2760(00)00304-0
  54. Jard S. Vasopressin: mechanisms of receptor activation. Progress in Brain Research. 1983;60:383-394.  https://doi.org/10.1016/S0079-6123(08)64405-2
  55. Ostrowski NL, Young WS 3rd, Knepper MA, Lolait SJ. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinology. 1993;133(4):1849-1859. https://doi.org/10.1210/endo.133.4.8404628
  56. Natochin YV, Golosova DV. Vasopressin receptor subtypes and renal sodium transport. Vitamins and Hormones. 2020;113:239-258.  https://doi.org/10.1016/bs.vh.2019.08.013
  57. Tagawa T, Imaizumi T, Endo T, Shiramoto M, Hirooka Y, Ando S, Takeshita A. Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels. The Journal of Clinical Investigation. 1993;92(3):1483-1490. https://doi.org/10.1172/JCI116726
  58. Deen PM, Verdijk MA, Knoers NV, Wieringa B, Monnens LA, van Os CH, van Oost BA. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science (New York NY.). 1994;264(5155):92-95.  https://doi.org/10.1126/science.8140421
  59. Moeller HB, Fuglsang CH, Fenton R A. Renal aquaporins and water balance disorders. Best Practice & Research. Clinical Endocrinology & Metabolism. 2016;30(2):277-288.  https://doi.org/10.1016/j.beem.2016.02.012
  60. Alehagen U, Dahlström U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011;305(20):2088-2095. https://doi.org/10.1001/jama.2011.666
  61. Tentzeris I, Jarai R, Farhan S, Perkmann T, Schwarz MA, Jakl G, Wojta J, Huber K. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. European Journal of Heart Failure. 2011; 13(7):726-733.  https://doi.org/10.1093/eurjhf/hfr049
  62. Zhong Y, Wang R, Yan L, Lin M, Liu X, You T. Copeptin in heart failure: Review and meta-analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2017;475:36-43.  https://doi.org/10.1016/j.cca.2017.10.001
  63. Frantz S, Störk S, Michels K, Eigenthaler M, Ertl G, Bauersachs J, Angermann CE. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. European Journal of Heart Failure. 2008;10(4):388-395. Epub 2008 Mar 17. PMID: 18343723. https://doi.org/10.1016/j.ejheart.2008.02.015
  64. Zile MR, Desantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, Mehurg SM, Spinale FG. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circulation. Heart Failure. 2011;4(3):246-256.  https://doi.org/10.1161/CIRCHEARTFAILURE.110.958199
  65. Gu X, Xu J, Yang XP, Peterson E, Harding P. Fractalkine neutralization improves cardiac function after myocardial infarction. Experimental Physiology. 2015;100(7):805-817.  https://doi.org/10.1113/EP085104
  66. Richter B, Koller L, Hohensinner PJ, Rychli K, Zorn G, Goliasch G, Berger R, Mörtl D, Maurer G, Huber K, Pacher R, Wojta J, Hülsmann M, Niessner A. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thrombosis and Haemostasis. 2012;108(6):1220-1227. Epub 2012 Sept 26. PMID: 23014777. https://doi.org/10.1160/TH12-03-0195
  67. Ji CL, Nomi A, Li, B, Shen C, Song BC, Zhang JG. Errata: Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance. International Heart Journal. 2019;60(4):1017. https://doi.org/10.1536/ihj.60-4_Errata
  68. Shao Z, Zhang R, Shrestha K, Borowski AG, Schuster A, Thakur A, Hazen SL, Tang W H. Usefulness of elevated urine neopterin levels in assessing cardiac dysfunction and exercise ventilation inefficiency in patients with chronic systolic heart failure. The American Journal of Cardiology. 2014;113(11):1839-1843. https://doi.org/10.1016/j.amjcard.2014.03.016
  69. Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Tabata N, Tsujita K, Yamamuro M, Kaikita K, Watanabe H, Hokimoto S, Maruyama T, Ogawa H. The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction. ESC Heart Failure. 2016;3(1):53-59.  https://doi.org/10.1002/ehf2.12070
  70. Lanser L, Pölzl G, Fuchs D, Weiss G, Kurz K. Neopterin is Associated with Disease Severity and Outcome in Patients with Non-Ischaemic Heart Failure. Journal of Clinical Medicine. 2019;8(12):2230. https://doi.org/10.3390/jcm8122230
  71. Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, Januzzi JL, Maisel AS, McDonald K, Mueller T, Richards AM, Seferovic P, Mueller C, de Boer RA. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). European Journal of Heart Failure. 2021;23(10):1610-1632. https://doi.org/10.1002/ejhf.2346
  72. Kourek C, Briasoulis A, Zouganeli V, Karatzanos E, Nanas S, Dimopoulos S. Exercise Training Effects on Circulating Endothelial and Progenitor Cells in Heart Failure. Journal of Cardiovascular Development and Disease. 2022;9(7):222.  https://doi.org/10.3390/jcdd9070222
  73. Sarhene M, Wang Y, Wei J, Huang Y, Li, M, Li, L, Acheampong E, Zhengcan Z, Xiaoyan Q, Yunsheng X, Jingyuan M, Xiumei G, Guanwei F. Biomarkers in heart failure: the past, current and future. Heart Failure Reviews. 2019 Nov;24(6):867-903. PMID: 31183637. https://doi.org/10.1007/s10741-019-09807-z
  74. Ahmad T, Felker GM. Galectin-3 in heart failure: more answers or more questions? Journal of the American Heart Association. 2012;1(5):e004374. https://doi.org/10.1161/JAHA.112.004374
  75. Ho, J. E, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. Journal of the American College of Cardiology. 2012;60(14):1249-1256. https://doi.org/10.1016/j.jacc.2012.04.053
  76. Ahmad T, Felker GM. Galectin-3 in heart failure: more answers or more questions? Journal of the American Heart Association. 2012;1(5):e004374. https://doi.org/10.1161/JAHA.112.004374
  77. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology. 2006;48(6):1217-1224. https://doi.org/10.1016/j.jacc.2006.03.061
  78. deFilippi CR, Christenson RH. Evolving role of galectin-3 as a cardiac biomarker: heart failure with preserved ejection fraction and renal function, important pieces of the puzzle. JACC. Heart Failure. 2015;3(3):253-256.  https://doi.org/10.1016/j.jchf.2014.12.009
  79. Zhong X, Qian X, Chen G, Song X. The role of galectin-3 in heart failure and cardiovascular disease. Clinical and Experimental Pharmacology & Physiology. 2019;46(3):197—203.  https://doi.org/10.1111/1440-1681.13048
  80. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clinical science (London, England: 1979). 2012;122(4):143-159.  https://doi.org/10.1042/CS20110340
  81. Frangogiannis NG. Cardiac fibrosis. Cardiovascular Research. 2021;117(6):1450-1488. https://doi.org/10.1093/cvr/cvaa324
  82. Shcherbo SN, Shcherbo DS, Kralin MYu. Biomarkers of personalized medicine. Part 5. Non-coding RNAs and microRNA. Medical Alphabet. 2015;3(11):5-11. (In Russ.).
  83. Parvan R, Hosseinpour M, Moradi Y, Devaux Y, Cataliotti A, da Silva GJJ. Diagnostic performance of microRNAs in the detection of heart failure with reduced or preserved ejection fraction: a systematic review and meta-analysis. European Journal of Heart Failure. 2022;24(12):2212-2225. https://doi.org/10.1002/ejhf.2700
  84. Kempf T, Wollert K C. Growth-differentiation factor-15 in heart failure. Heart Failure Clinics. 2009;5(4):537-547.  https://doi.org/10.1016/j.hfc.2009.04.006
  85. Li J, Cui Y, Huang A, Li, Q, Jia W, Liu K, Qi X. Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure. Medical Science Monitor: international medical journal of experimental and clinical research. 2018;24:4992-4999. https://doi.org/10.12659/MSM.910671
  86. Sawalha K, Norgard NB, Drees BM, López-Candales A. Growth Differentiation Factor 15 (GDF-15), a New Biomarker in Heart Failure Management. Current Heart Failure Reports. 2023;20(4): 287-299.  https://doi.org/10.1007/s11897-023-00610-4
  87. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. The New England Journal of Medicine. 2002;347(3):161-167.  https://doi.org/10.1056/NEJMoa020233
  88. Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F, Januzzi J, Rosenberg J, Senior R, Richards M. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. European Heart Journal. 2010;31(15):1881-1889. https://doi.org/10.1093/eurheartj/ehq163
  89. Idzikowska K, Zielińska M. Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease. The Journal of International Medical Research. 2018;46(8):3017-3029. https://doi.org/10.1177/0300060518786907
  90. Dudek M, Kałużna-Oleksy M, Migaj J, Sawczak F, Krysztofiak H, Lesiak M, Straburzyńska-Migaj E. sST2 and Heart Failure-Clinical Utility and Prognosis. Journal of Clinical Medicine, 2023;12(9):3136. https://doi.org/10.3390/jcm12093136
  91. Khadeja Bi, A, Santhosh V, Sigamani K. Levels of Galectin-3 in Chronic Heart Failure: A Case-Control Study. Cureus, 2022;14(8): e28310. https://doi.org/10.7759/cureus.28310
  92. Lyle MA, Iyer SR, Redfield MM, Reddy YNV, Felker GM, Cappola TP, Hernandez AF, Scott CG, Burnett JC Jr, Pereira NL. Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. JACC. Heart Failure, 2020;8(1):70-80.  https://doi.org/10.1016/j.jchf.2019.07.005
  93. Schill F, Timpka S, Nilsson PM, Melander O, Enhörning S. Copeptin as a predictive marker of incident heart failure. ESC Heart Failure. 2021;8(4):3180-3188. https://doi.org/10.1002/ehf2.13439
  94. Ji CL, Nomi A, Li B, Shen C, Song BC, Zhang JG. Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance. International Heart Journal. 2019;60(3): 701-707.  https://doi.org/10.1536/ihj.18-422
  95. Loh SX, Ekinci Y, Spray L, Jeyalan V, Olin T, Richardson G, Austin D, Alkhalil M, Spyridopoulos I. Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease. Journal of Clinical Medicine. 2023;12(14):4821. https://doi.org/10.3390/jcm12144821
  96. Chia YC, Kieneker LM, van Hassel G, Binnenmars SH, Nolte IM, van Zanden JJ, van der Meer P, Navis G, Voors AA, Bakker SJL, De Borst MH, Eisenga MF. Interleukin 6 and Development of Heart Failure With Preserved Ejection Fraction in the General Population. Journal of the American Heart Association. 2021;10(11): e018549. https://doi.org/10.1161/JAHA.120.018549
  97. Du W, Piek A, Schouten EM, van de Kolk CWA, Mueller C, Mebazaa A, Voors AA, de Boer RA, Silljé HHW. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics. 2018;8(15):4155-4169. https://doi.org/10.7150/thno.26055
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.